ABBV vs CNMD

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

CNMD exhibits a stark divergence between its strong balance sheet health (Piotroski F-Score: 7/9) and its deteriorating operational performance. While the company maintains a stable financial foundation and a low Price-to-Sales ratio, it is plagued by a severe earnings collapse (-50% YoY) and a consistent track record of missing analyst estimates (0/4 beats in the last year). With the current price ($38.34) trading above the Graham Number ($33.66) and significantly above the growth-based intrinsic value ($10.57), the stock lacks a valuation catalyst despite a low forward P/E.